ClinicalTrials.gg
TerminatedNCT03584009VeronicaUpdated Jun 28, 2022Results posted

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

A Phase 2 interventional study of Venetoclax and Fulvestrant in Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer, sponsored by Hoffmann-La Roche. Terminated at 40 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-28.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor's decision, no safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 229 studies in Breast Neoplasms by Hoffmann-La Roche — 16 open to participants now, 28 under way, 13 of them phase 3. Breast Neoplasms · Hoffmann-La Roche.

Enrollment
102nd of 170
103 · median 151
Started
2018
with 7 others
Phase 2
65 of 229
4 open now
Registered
186th of 229
by date

Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 102nd largest by enrollment of the 170 interventional ones that give a count, is one of 8 that started in 2018, is one of 65 in phase 2, and was the 186th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

16 of the 229 studies in Breast Neoplasms by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 229 studies in Breast Neoplasms by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This is a Phase II, multicenter, open-label, randomized study to compare the efficacy of venetoclax in combination with fulvestrant compared with fulvestrant alone in women with ER+, HER2-negative, locally advanced or Metastatic Breast Cancer (MBC) who experienced disease recurrence or progression during or after treatment with CDK4/6i therapy for at least 8 weeks. As of 9th October 2020, participants in the Venetoclax + Fulvestrant arm, have all discontinued Venetoclax treatment and have continued on Fulvestrant treatment alone.

03

Conditions studied

  • Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological confirmation of estrogen receptor-positive (ER+) invasive carcinoma of the breast. ER+, - negative invasive carcinoma of the breast with evaluable sample for BCL-2 IHC value at the time of screening. Participants who were originally diagnosed with HER2-positive breast cancer that converted to HER2-negative MBC are not eligible.
  • Evidence of or locally advanced disease not amenable to surgical or local therapy with curative intent.
  • Be or pre- or perimenopausal women amenable to being treated with the luteinizing hormone-releasing hormone (LHRH) agonist goserelin.
  • Participants must not have received more than two prior lines of hormonal therapy in the locally advanced or metastatic setting. In addition, at least one must be a CDK4/6i AND participants must have experienced disease recurrence or progression during or after CDK4/6i therapy, which must have been administered for a minimum of 8 weeks prior to progression.
  • Participants for whom endocrine therapy (e.g., fulvestrant) is recommended and treatment with cytotoxic chemotherapy is not indicated at the time of entry into the study, as per national or local treatment guidelines.
  • Women of (i.e., not postmenopausal for at least 12 months or surgically sterile) must have had a negative serum pregnancy test result at screening, within 14 days prior to the first study drug administration.
  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use non-hormonal methods with a failure rate of \<1% per year during the treatment period and for up to 2 years after the last dose of study drug (or based on the local prescribing information for fulvestrant). Women must refrain from donating eggs during this same period.
  • Willing to provide tumor sample.
  • Had at least one via v1.1.
  • Had an (ECOG) Performance Score of 0-1.
  • Had adequate organ and marrow function.
  • Had a > 3 months.
  • To full fill the coagulation requirements for patient with or without therapeutic anticoagulation.

Exclusion criteria

Exclusion criteria:

  • Prior treatment with fulvestrant or other selective estrogen receptor degraders (SERDs), venetoclax, or any agent whose mechanism of action is to inhibit BCL-2.
  • Pregnant, lactating, or intending to become pregnant during the study.
  • Known untreated or active Central Nervous System (CNS) (progressing or requiring anticonvulsants or for symptomatic control.
  • Prior chemotherapy in the locally advanced or metastatic setting regardless of the duration of the treatment.
  • Any anti-cancer therapy received within 21 days of the first dose of study drug, including chemotherapy, radiotherapy, hormonal therapy, immunotherapy, antineoplastic vaccines, or other therapy. (Radiotherapy with palliative intent to non-target sites is allowed).
  • Concurrent radiotherapy to any site or prior radiotherapy within 21 days of Cycle 1 Day 1 or previous radiotherapy to the target lesion sites (the sites that are to be followed for determination of a response) or prior radiotherapy to > 25% of bone marrow.
  • Current severe, uncontrolled, systemic disease (e.g., cardiovascular, pulmonary, metabolic or infectious disease.
  • Any major surgery within 28 days of the first dose of study drug or anticipation of the need for major surgery during the course of study treatment.
  • Consumption of one or more of the following within 3 days prior to the first dose of study drug: Grapefruit or grapefruit products; Seville oranges including marmalade containing Seville oranges; Star fruit (carambola).
  • Administration within 7 days prior first dose of study treatment of Steroid therapy for anti-neoplastic intent, Strong or moderate inhibitors or Strong or moderate CYP3A inducers.
  • Need for current chronic corticosteroid therapy (> 10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids).
  • Known infection with () HIV or human T-cell leukemia virus 1.
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1 Day).
  • Positive test results for core antibody (HBcAb) or virus (HCV) antibody at screening. Participants who were positive for HCV antibody should have been negative for HCV by PCR to be eligible for study participation. Participants with a past or resolved hepatitis B virus (HBV) infection (defined as having a positive total HBcAb and negative hepatitis B surface antigen [HbsAg]) may be included if HBV DNA is undetectable. These participants should have been willing to undergo monthly DNA testing.
  • Participants who had a positive HCV antibody test are eligible for the study if a PCR assay is negative for HCV RNA.
  • History of other within the past 5 years except for treated skin basal cell carcinoma, squamous cell carcinoma, non-malignant melanoma \<= 1.0 mm without ulceration, localized thyroid cancer, or cervical carcinoma in-situ.
  • Administration of a live, attenuated vaccine within 4 weeks prior to initiation of study treatment or anticipation of need for such a vaccine during the study.
  • Cardiopulmonary dysfunction.
  • Other medical or psychiatric conditions that, in the opinion of the investigatory, may interfere with the participant's participation in the study.
  • Inability or unwillingness to swallow pills or receive intramuscular (IM) injections.
  • History of malabsorption syndrome or other condition that would interfere with enteral absorption.
  • History of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) or active bowel inflammation (e.g., diverticulitis).
  • Concurrent hormone replacement therapy.
  • Inability to comply with study and follow-up procedures.
  • History or active cardiopulmonary dysfunction.
  • Known to any of the study medications (fulvestrant, venetoclax) or to any of the .
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    Venetoclax + Fulvestrant

    Participants were administered Venetoclax 800mg orally once daily (QD) and Fulvestrant 500mg intramuscularly (IM) on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).

    Drug: Venetoclax · Drug: Fulvestrant

  • Active comparator
    Fulvestrant

    Participants were administered Fulvestrant 500mg only IM on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).

    Drug: Fulvestrant

Interventions

  • Venetoclax was administered orally, 800-mg tablet beginning on Cycle 1 Day 1 until the 9th October 2020.

  • Fulvestrant was administered orally, 500 mg administered as two 250-mg IM injections on Cycle 1 Days 1 and 15 and on Day 1 of each subsequent 28-day cycle

06

What researchers measure

Primary outcomes

  1. Clinical Benefit Defined as Complete Response (CR), Partial Response (PR) or Stable Disease (SD) Lasting >= 24 Weeks, as Determined by the Investigator According to RECIST v1.1

    Clinical Benefit was defined as CR, PR, or SD lasting more than equal to 24 weeks from randomization in participants with measurable disease at baseline, as determined by the investigator according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1. Per RECIST v1.1 for target lesions assessed by CT or MRI: CR, Disappearance of all target lesions; PR, PR \>= 30% decrease in the sum of diameters of target lesions (TL) taking as reference the baseline sum of diameters; SD, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Disease Progression (PD), PD\>= 20% increase in the sum of diameters of TL taking as reference the smallest sum on study(Nadir). In addition to the relative increase of 20% sum must have demonstrate an absolute increase of at least 5mm.

    Time frame: Randomization through till 6 months after the last participant is enrolled into the study (up to approximately 23 months)

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time from randomization to the first occurrence of disease progression (as determined by the investigator according to RECIST v1.1) or death from any cause, whichever occurs first.

    Time frame: Randomization through till 6 months after the last participant is enrolled into the study (up to approximately 23 months)

  2. Objective Response (OR)

    OR was defined as CR or PR, in participants with measurable disease at baseline as determined by the investigator according to RECIST v1.1.

    Time frame: Randomization through till 6 months after the last participant is enrolled into the study (up to approximately 23 months)

  3. Duration of Response (DOR)

    DOR was defined as the time from the first occurrence of a documented objective response to the time of the first documented disease progression (as determined by the investigator according to RECIST v1.1) or death from any cause, whichever occurs first.

    Time frame: Time from first occurrence of a documented objective response to the first documented disease progression or death from any cause, whichever occurs first, until 6 months after the last participant is enrolled in the study (up to approximately 23 months)

  4. Overall Survival (OS)

    OS was defined as the time from randomization to death due to any cause.

    Time frame: Randomization to death from any cause, through till the end of the study (up to approximately 32 months)

  5. Percentage of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study were also considered as AEs.

    Time frame: Baseline up until 28 days after the last dose of study drug (venetoclax or fulvestrant, whichever is later) up to approximately 32 months

  6. Plasma Concentrations of Venetoclax

    Time frame: Cycle 1 Day 1: 4 hours (hrs) post-dose; Cycle 2 Day 1: pre-dose (within 1 hr) and 2, 4, 6, 8 hrs post-dose; any time during visits up to study drug discontinuation/Early Termination (up to approximately 32 months)

  7. Plasma Concentrations of Fulvestrant (in Presence of Venetoclax)

    Time frame: Cycle 2 Day 1: pre-dose (within 1 hr); Cycle 6 Day 1: pre-dose (within 1 hr); any time during visits up to study drug discontinuation/Early Termination (up to approximately 32 months)

  8. Plasma Concentrations of Fulvestrant (in Absence of Venetoclax)

    Time frame: Cycle 2 Day 1: pre-dose (within 1 hr); any time during visits up to study drug discontinuation/Early Termination (up to approximately 32 months)

07

Results

Posted Sep 27, 2021
Limitations and caveats
The study was terminated due to Sponsor's decision and there were no safety concerns. Primary and secondary efficacy endpoints have been updated to report 95% confidence interval (CI) for Clinical Benefit estimate and 95% CI for the Cox proportional hazards model for PFS, following reporting conventions.

Participant flow

The study was conducted at 38 centers in 5 countries.

Participant flow — Overall Study
MilestoneVenetoclax + FulvestrantFulvestrant
Started5152
Completed00
Not completed5152
Withdrew: Death2518
Withdrew: Lost to follow-up01
Withdrew: Physician decision11
Withdrew: Study terminated by sponsor2230
Withdrew: Withdrawal by subject32

Outcome measures

PrimaryClinical Benefit Defined as Complete Response (CR), Partial Response (PR) or Stable Disease (SD) Lasting >= 24 Weeks, as Determined by the Investigator According to RECIST v1.1

Clinical Benefit was defined as CR, PR, or SD lasting more than equal to 24 weeks from randomization in participants with measurable disease at baseline, as determined by the investigator according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1. Per RECIST v1.1 for target lesions assessed by CT or MRI: CR, Disappearance of all target lesions; PR, PR \>= 30% decrease in the sum of diameters of target lesions (TL) taking as reference the baseline sum of diameters; SD, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Disease Progression (PD), PD\>= 20% increase in the sum of diameters of TL taking as reference the smallest sum on study(Nadir). In addition to the relative increase of 20% sum must have demonstrate an absolute increase of at least 5mm.

Time frame:
Randomization through till 6 months after the last participant is enrolled into the study (up to approximately 23 months)
Reported as:
Number · Percentage of Participants
Clinical Benefit Defined as Complete Response (CR), Partial Response (PR) or Stable Disease (SD) Lasting >= 24 Weeks, as Determined by the Investigator According to RECIST v1.1
Percentage of ParticipantsVenetoclax + FulvestrantFulvestrant
Clinical Benefit Defined as Complete Response (CR), Partial Response (PR) or Stable Disease (SD) Lasting >= 24 Weeks, as Determined by the Investigator According to RECIST v1.111.8 (4.44 to 23.87)13.7 (5.70 to 26.26)
Statistical analysis
  • Venetoclax + Fulvestrant vs Fulvestrant · Cochran-Mantel-Haenszel · p = 0.7286 (P-value is based on Stratified Analysis (Stratified by BCL2 status (High vs Low) and Lines of Therapy (2 vs 1)).) · Risk difference (rd): -1.96 · 95% CI -16.86 to 12.94
SecondaryProgression Free Survival (PFS)

PFS was defined as the time from randomization to the first occurrence of disease progression (as determined by the investigator according to RECIST v1.1) or death from any cause, whichever occurs first.

Time frame:
Randomization through till 6 months after the last participant is enrolled into the study (up to approximately 23 months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsVenetoclax + FulvestrantFulvestrant
Progression Free Survival (PFS)2.69 (1.94 to 3.71)1.94 (1.84 to 3.55)
Statistical analysis
  • Venetoclax + Fulvestrant vs Fulvestrant · Regression, Cox · p = 0.7853 (P-value is based on Stratified Analysis (Stratified by BCL2 status (High vs Low) and Lines of Therapy (2 vs 1)).) · Hazard ratio (hr): 0.94 · 95% CI 0.61 to 1.45
SecondaryObjective Response (OR)

OR was defined as CR or PR, in participants with measurable disease at baseline as determined by the investigator according to RECIST v1.1.

Time frame:
Randomization through till 6 months after the last participant is enrolled into the study (up to approximately 23 months)
Reported as:
Number · Percentage of Participants
Objective Response (OR)
Percentage of ParticipantsVenetoclax + FulvestrantFulvestrant
Objective Response (OR)3.9 (0.48 to 13.46)5.9 (1.23 to 16.24)
Statistical analysis
  • Venetoclax + Fulvestrant vs Fulvestrant · Cochran-Mantel-Haenszel · p = 0.5978 (P-value is based on Stratified Analysis (Stratified by BCL2 status (High vs Low) and Lines of Therapy (2 vs 1)).) · Risk difference (rd): -1.96 · 95% CI -12.29 to 8.37
SecondaryDuration of Response (DOR)

DOR was defined as the time from the first occurrence of a documented objective response to the time of the first documented disease progression (as determined by the investigator according to RECIST v1.1) or death from any cause, whichever occurs first.

Time frame:
Time from first occurrence of a documented objective response to the first documented disease progression or death from any cause, whichever occurs first, until 6 months after the last participant is enrolled in the study (up to approximately 23 months)
Reported as:
Median · Months
Duration of Response (DOR)
MonthsVenetoclax + FulvestrantFulvestrant
Duration of Response (DOR)NA (NA to NA)3.61 (1.94 to NA)
SecondaryOverall Survival (OS)

OS was defined as the time from randomization to death due to any cause.

Time frame:
Randomization to death from any cause, through till the end of the study (up to approximately 32 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsVenetoclax + FulvestrantFulvestrant
Overall Survival (OS)19.71 (13.73 to NA)NA (20.93 to NA)
Statistical analysis
  • Venetoclax + Fulvestrant vs Fulvestrant · Log Rank · p = 0.0403 (P-value is based on Stratified Analysis (Stratified by BCL2 status (High vs Low) and Lines of Therapy (2 vs 1)).) · Hazard ratio (hr): 1.87 · 95% CI 1.02 to 3.43Hazard ratios were estimated by Cox regression.
SecondaryPercentage of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study were also considered as AEs.

Time frame:
Baseline up until 28 days after the last dose of study drug (venetoclax or fulvestrant, whichever is later) up to approximately 32 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Events (AEs)
Percentage of ParticipantsVenetoclax + FulvestrantFulvestrant
Percentage of Participants With Adverse Events (AEs)94.076.5
SecondaryPlasma Concentrations of Venetoclax
Time frame:
Cycle 1 Day 1: 4 hours (hrs) post-dose; Cycle 2 Day 1: pre-dose (within 1 hr) and 2, 4, 6, 8 hrs post-dose; any time during visits up to study drug discontinuation/Early Termination (up to approximately 32 months)
Reported as:
Geometric mean · Micrograms per Milliliters (μg/mL)
Plasma Concentrations of Venetoclax
Micrograms per Milliliters (μg/mL)Venetoclax
Cycle 1 Day 1: 4 hrs post-dose1.78 ± 61.8
Cycle 2 Day 1: pre-dose1.04 ± 85.4
Cycle 2 Day 1: 2 hrs post-dose1.45 ± 74.1
Cycle 2 Day 1: 4 hrs post-dose2.51 ± 57.2
Cycle 2 Day 1: 6 hrs post-dose3.32 ± 56.4
Cycle 2 Day 1: 8 hrs post-dose3.55 ± 57.8
Treatment discontinuation visit0.0112 ± NA
SecondaryPlasma Concentrations of Fulvestrant (in Presence of Venetoclax)
Time frame:
Cycle 2 Day 1: pre-dose (within 1 hr); Cycle 6 Day 1: pre-dose (within 1 hr); any time during visits up to study drug discontinuation/Early Termination (up to approximately 32 months)
Reported as:
Geometric mean · μg/mL
Plasma Concentrations of Fulvestrant (in Presence of Venetoclax)
μg/mLFulvestrant
Cycle 2 Day 1: pre-dose0.0129 ± 37.1
Cycle 6 Day 1: pre-dose0.0145 ± 31.8
Treatment discontinuation visit0.00985 ± 29.1
SecondaryPlasma Concentrations of Fulvestrant (in Absence of Venetoclax)
Time frame:
Cycle 2 Day 1: pre-dose (within 1 hr); any time during visits up to study drug discontinuation/Early Termination (up to approximately 32 months)
Reported as:
Geometric mean · μg/mL
Plasma Concentrations of Fulvestrant (in Absence of Venetoclax)
μg/mLFulvestrant
Cycle 2 Day 1: pre-dose0.0103 ± 29.4
Treatment discontinuation visit0.0139 ± NA

Adverse events

Collected over Baseline up until 28 days after the last dose of study drug (venetoclax or fulvestrant, whichever is later) up to approximately 32 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Venetoclax + Fulvestrant26/51 (51%)4/50 (8%)45/50 (90%)
Fulvestrant18/52 (34.6%)2/51 (3.9%)34/51 (66.7%)
Most frequent serious events
Most frequent serious events
EventVenetoclax + FulvestrantFulvestrant
PyrexiaGeneral disorders1/500/51
Lower respiratory tract infectionInfections and infestations1/500/51
UrosepsisInfections and infestations1/500/51
Ejection fraction decreasedInvestigations1/500/51
Flank painMusculoskeletal and connective tissue disorders0/501/51
Pleural effusionRespiratory, thoracic and mediastinal disorders0/501/51
Bone painMusculoskeletal and connective tissue disorders0/501/51
Most frequent other events
Showing 10 of 36
Most frequent other events
EventVenetoclax + FulvestrantFulvestrant
NauseaGastrointestinal disorders32/509/51
DiarrhoeaGastrointestinal disorders28/505/51
FatigueGeneral disorders18/509/51
VomitingGastrointestinal disorders15/501/51
Injection site reactionGeneral disorders11/5015/51
Decreased appetiteMetabolism and nutrition disorders9/502/51
Hot flushVascular disorders1/509/51
NeutropeniaBlood and lymphatic system disorders8/500/51
ConstipationGastrointestinal disorders8/502/51
InsomniaPsychiatric disorders8/504/51

Baseline characteristics

Intent-To-Treat (ITT) population included all randomized participants whether or not they were assigned to the arm where the study treatment was administered.

Age, Continuous
Age, Continuous(years)Venetoclax + FulvestrantFulvestrantTotal
Mean57.4 ± 10.658.8 ± 11.758.1 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Venetoclax + FulvestrantFulvestrantTotal
Female5152103
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Venetoclax + FulvestrantFulvestrantTotal
Hispanic or Latino134
Not Hispanic or Latino474693
Unknown or Not Reported336
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Venetoclax + FulvestrantFulvestrantTotal
American Indian or Alaska Native000
Asian639
Native Hawaiian or Other Pacific Islander000
Black or African American325
White404686
More than one race101
Unknown or Not Reported112
08

Study locations

40 sites
  • Mayo Clinic Hospital
    Phoenix, Arizona 85054, United States
  • Highlands Oncology Group
    Springdale, Arkansas 72762, United States
  • UC San Deigo Moores Cancer Center
    La Jolla, California 92037, United States
  • Comprehensive Cancer Center at Desert Regional Medical Center
    Palm Springs, California 92262, United States
  • St. Joseph Health Medical Group - Annadel Medical Group
    Santa Rosa, California 95403-1757, United States
  • Sylvester Comprehensive Cent.
    Miami, Florida 33136, United States
  • Northwest Georgia Oncology Centers PC - Marietta
    Marietta, Georgia 30060, United States
  • Kaiser Permanente - Moanalua Medical Center
    Honolulu, Hawaii 96819-1469, United States
  • Ashland-Bellefonte Cancer Center
    Ashland, Kentucky 41101-7016, United States
  • University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
  • Massachusetts General Hospital.
    Boston, Massachusetts 02114, United States
  • Mass General/North Shore Cancer
    Peabody, Massachusetts 01960, United States
  • Abbott Northwestern Hospital
    Minneapolis, Minnesota 55407, United States
  • Nebraska Hematology Onco, PC
    Lincoln, Nebraska 68506, United States
  • University of New Mexico Cancer Center
    Albuquerque, New Mexico 87131, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Sanford Health System
    Sioux Falls, South Dakota 57105, United States
  • The University of Texas Southwestern Medical Center at Dallas
    Dallas, Texas 75390, United States
  • The Center for Cancer and Blood Disorders - Fort Worth
    Fort Worth, Texas 76104, United States
  • Millennium Research & Clinical Development
    Houston, Texas 77090, United States
  • Providence Regional Cancer Partnership
    Everett, Washington 98201, United States
  • Mater Hospital; Patricia Ritchie Centre for Cancer Care and Research
    North Sydney, New South Wales 2059, Australia
  • Mater Misericordiae Limited
    South Brisbane, Queensland 4101, Australia
  • Peter MacCallum Cancer Center
    North Melbourne, Victoria 3051, Australia
  • Southlake Regional Health Center
    Newmarket, Ontario L3Y 2R2, Canada
  • The Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • Centre Hospitalier Universitaire de Sherbrooke - Hopital Fleurimont
    Sherbrooke, Quebec J1H 5N4, Canada
  • Hämato-Onkologische Schwerpunktpraxis am Klinikum Aschaffenburg
    Aschaffenburg, 63739, Germany
  • Universitätsklinikum Erlangen; Frauenklinik
    Erlangen, 91054, Germany
  • Klinikum Frankfurt Höchst GmbH
    Frankfurt, 65929, Germany
  • Facharztzentrum Eppendorf, Studien GbR
    Hamburg, 20249, Germany
  • Rotkreuzklinikum München; Frauenklinik
    Muenchen, 80637, Germany
  • Gemeinschaftspraxis für Hämatologie und Onkologie GbR; Dechow & Decker & Nonnenbroich
    Ravensburg, 88212, Germany
  • Klinikum Südstadt Rostock
    Rostock, 18059, Germany
  • Royal United Hospital Bath NHS Trust
    Bath, BA1 3NG, United Kingdom
  • Royal Sussex County Hospital
    Brighton, BN2 5BE, United Kingdom
  • Barts Health NHS Trust - St Bartholomew's Hospital
    London, EC1A 7BE, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
  • Nottingham University Hospitals NHS Trust - City Hospital
    Nottingham, NG5 1PB, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Aug 2020, 22 months.

Results were first posted in Sep 2021, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2018
First posted
Jul 12, 2018
StartActual
Sep 6, 2018
Primary completionActual
Aug 5, 2020
CompletionActual
May 6, 2021
Results first posted
Sep 27, 2021
Last update
Jun 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03584009
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 12, 2018
Start date
Sep 6, 2018
Primary completion
Aug 5, 2020
Completion
May 6, 2021
Results posted
Sep 27, 2021
Last update
Jun 28, 2022

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion